1. Systemic treatment and new developments in advanced prostate cancer;Sternberg;Eur. J. Cancer,2001
2. Chemotherapy of urologic malignancies;Scher;Semin. Urol.,1985
3. Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients;Collette;Eur. J. Cancer,2001
4. The development of biologic end points in patients treated with differentiation agents;Kelly;Clin. Cancer Res.,2000
5. Abarelix depot, a pure GnRH antagonist, compared to LHRH agonist in patients with prostate cancer;Debruyne;Eur. Urol.,2000